Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation

Thrombosis Research

Volumn 116, Issue 3, 2005, Pages 233-240

  Pihusch, Verena ^a   Pihusch, Markus ^a   Penovici, Marius ^a   Kolb, Hans J ^a   Hiller, Erhard ^a   Pihusch, Rudolf ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Endothelial cells; Plasminogen activator inhibitor 1; Platelets; Tissue factor; Transforming growth factor beta 1; Veno occlusive disease

Indexed keywords

CD40 LIGAND; IMMUNOGLOBULIN G ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; TRANSFORMING GROWTH FACTOR BETA1;

ANTIBODY SPECIFICITY; ARTICLE; CELL ISOLATION; CELL SURFACE; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; INCUBATION TIME; LIVER VENOOCCLUSIVE DISEASE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RELEASE REACTION; UMBILICAL CORD;

BLOOD PLATELETS; CELL COMMUNICATION; CELLS, CULTURED; COCULTURE TECHNIQUES; ENDOTHELIUM, VASCULAR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MODELS, BIOLOGICAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET ACTIVATION; THROMBOPHILIA; THROMBOPLASTIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UMBILICAL CORD;

EID: 20144366170     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.12.010     Document Type: Article

References (47)

1. G.B. McDonald, P. Sharma, D.E. Matthews, H.M. Shulman, and E.D. Thomas Venoocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors Hepatology 4 1 1984 116 122
2. R. Jones, K.S.K. Lee, W.E. Beschorner, V.G. Vogel, L.B. Grochow, and H.G. Braine Venoocclusive disease of the liver following bone marrow transplantation Transplantation 44 6 1987 778 783
3. E.M. Faioni, and P.M. Mannucci Venoocclusive disease of the liver after bone marrow transplantation: the role of hemostasis Leuk. Lymphoma 25 1997 233 245
4. E. Carreras, H. Bertz, W. Arcese, J.P. Vernant, J.F. Tomas, and H. Hagglund Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European group for blood and marrow transplantation. European group for blood and marrow transplantation chronic leukemia working party Blood 15 1998 3599 3604
5. E. Holler, H.J. Kolb, A. Möller, J. Kempeni, S. Liesenfeld, and H. Pechumer Increased serum levels of tumor necrosis factor α precede major complications of bone marrow transplantation Blood 75 4 1990 1011 1016
6. G.E. Gifford, and D.A. Flick Natural production and release of tumor necrosis factor Ciba Found. Symp. 131 1987 3 20
7. H. Oh, T. Tahara, M. Bouvier, A. Farrand, and G.B. McDonald Plasma thrombopoietin levels in marrow transplantant patients with veno-occlusive disease of the liver Bone Marrow Transplant. 22 1998 675 679
8. B. Rio, G. Andreu, A. Nicod, J.P. Arrago, F. Dutrillaux, and M. Samama Thrombocytopenia in venoocclusive disease after bone marrow transplantation or chemotherapy Blood 67 6 1986 1773 1776
9. E.A. Jaffé, R.L. Nachman, C.G. Becker, and C.R. Minick Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria J. Clin. Invest. 52 1973 2745 2756
10. E.K.O. Kruithof Plasminogen activator inhibitors-a review Enzyme 40 1988 113 121
11. E.D. Sprengers, and C. Kluft Plasminogen activator inhibitors Blood 69 2 1987 381 387
12. C. Krishnamurti, and B.M. Alving Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo Semin. Thromb. Hemost. 18 1 1992 67 80
13. C. Kluft, J.H. Verheijen, A.F.H. Jie, D.C. Rijken, F.E. Preston, and H.M. Sue-Ling The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast acting inhibitor of tissue-type plasminogen activator after trauma Scand. J. Clin. Lab. Invest. 45 1985 605
14. W. Nürnberger, I. Michelmann, S. Burdach, and U. Göbel Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications Ann. Hematol. 76 1998 61 65
15. C. Salat, E. Holler, H.J. Kolb, R. Pihusch, B. Reinhardt, and M. Penovici The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation Leuk. Lymphoma 33 1-2 1999 25 32
16. C. Salat, E. Holler, H.J. Kolb, B. Reinhardt, R. Pihusch, and W. Wilmanns Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation Blood 89 6 1997 2184 2188
17. J.H. Lee, K.H. Lee, S. Kim, J.S. Lee, W.K. Kim, and C.J. Park Relevance of proteins C and S, antithrombin III, von Willebrand factor and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study Bone Marrow Transplant. 22 1998 883 888
18. P.L. Harper, J. Jarvis, I. Jennings, R. Luddington, and R.E. Marcus Changes in the natural anticoagulants following bone marrow transplantation Bone Marrow Transplant. 5 1990 39 42
19. E. Carreras Venoocclusive disease of the liver after hemopoietic cell transplantation Eur. J. Haematol. 64 2000 281 291
20. E. Holler, H.J. Kolb, M. Mittermüller, M. Kaul, G. Ledderose, and T. Duell Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNF α) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF α (MAK 195 F) Blood 86 3 1995 890 899
21. E. Holler, B. Ertl, R. Hintermeier-Knabe, M.G. Roncardo, G. Eissner, and F. Mayer Inflammatory reactions induced by pretransplant conditioning-an alternative target for modulation of acute GvHD and complications following allogeneic bone marrow transplantation? Leuk. Lymphoma 25 1996 217 224
22. V.W. Van Hinsberg, T. Kooistra, E.A. Van-den-Berg, E.M. Princen, W. Fiers, and J.J. Emeis Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo Blood 72 5 1998 1467 1473
23. H. Matsumoto, S. Ueshima, H. Fukao, Y. Mitsui, and O. Matsuo Effects of lipopolysaccharide on the expression of fibrinolytic factors in an established cell line from human endothelial cells Life Sci. 59 2 1996 85 96
24. J.S. Rao, A. Rayford, A. Yamamoto, K.K. Ang, P. Tofilon, and R. Sawaya Modulation of fibrinolysis by ionizing radiation J. Neuro-Oncol. 22 2 1994 161 171
25. V. Henn, J.R. Slupsky, M. Gräfe, I. Anagnostopoulos, R. Förster, and G. Müller-Berghaus CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells Nature 391 6667 1998 591 594
26. D. Hollenbaugh, N. Mischel-Petty, C.P. Edwards, J.C. Simon, R.W. Denfeld, and P.A. Kiener Expression of functional CD40 by vascular endothelial cells J. Exp. Med. 132 1 1995 33 40
27. J.R. Slupsky, M. Kalbas, A. Willuweit, V. Henn, R. Kroczek, and G. Müller-Berghaus Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40 Thromb. Haemost. 80 6 1998 1008 1014
28. M.S. Pepper, D. Belin, R. Montesano, L. Orci, and J.D. Vassalli Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro J. Cell Biol. 111 1990 743 755
29. S.M. Wileman, N.A. Booth, N. Moore, B. Redmill, J.V. Forrester, and R.M. Knott Regulation of plasminogen activation by TGF-beta in cultured human retinal endothelial cells Br. J. Ophthalmol. 84 4 2000 417 422
30. D.J. Grainger, D.E. Mosedale, and J.C. Metcalfe TGF β in blood: a complex problem Cytokine Growth Factor Rev. 11 2000 133 145
31. K.E. DeVisser, and W.M. Kast Effects of TGF β on the immune system: implications for cancer immunotherapy Leukemia 13 1999 1188 1199
32. F.M. Kong, M.S. Anscher, T. Murase, B.D. Abbott, J.D. Iglehart, and R.L. Jirtle Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor Ann. Surg. 222 2 1995 155 162
33. T. Murase, R.L. Jirtle, and G.B. McDonald Transforming growth factor-beta plasma concentrations in patients with leukemia and lymphoma receiving chemoradiotherapy and marrow transplantation Blood 83 8 1994 2383
34. X.L. Wang, S.X. Liu, and D.E. Licken Transforming growth factor beta 1 and coronary artery disease Cardiovasc. Res. 34 2 1997 404 410
35. T.J. Broekelmann, A.H. Limper, T.V. Colby, and J.A. McDonald Transforming growth factor β-1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis Proc. Natl. Acad. Sci. 88 1991 6642 6646
36. A. Castilla, J. Prieto, and N. Fausto Transforming growth factors β-1 and α in chronic liver disease: effects of interferon alfa therapy N. Engl. J. Med. 324 14 1991 933 940
37. J. Floege, E. Eng, B.A. Young, and R.J. Johnson Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo Kidney Int. 43 Suppl. 39 1993 47 54
38. M.C. Martyré TGF-β and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders Leuk. Lymphoma 20 1995 39 44
39. M.S. Anscher, W.P. Peters, H. Reisenbichler, W.P. Petros, and R.L. Jirtle Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer N. Engl. J. Med. 328 22 1993 1592 1598
40. T. Murase, M.S. Anscher, W.P. Petros, W.P. Peters, and R.L. Jirtle Changes in plasma transforming growth factor beta in response to high-dose chemotherapy for stage II breast cancer: possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicity Bone Marrow Transplant. 15 1995 173 178
41. H.M. Shulman, L.B. Fisher, G. Schoch, K. Henne, and G.B. McDonald Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms Hepatology 19 5 1994 1171 1180
42. H.M. Shulman, A.M. Gown, and D.J. Nugent Hepatic veno-occlusive disease after bone marrow transplantation: immunohistochemical identification of the material within occluded central venules Am. J. Pathol. 127 3 1987 549 558
43. J.H. Lee, K.H. Lee, J.H. Lee, S. Kim, M. Seol, and C.J. Park Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulfan and cyclophosphamide Br. J. Haematol. 118 2002 1087 1094
44. S.I. Bearman The syndrome of hepatic veno-occlusive disease after marrow transplantation Blood 85 1995 3005 3020
45. P. Richardson, C. Murakami, Z. Jin, D. Warren, P. Momtaz, and D. Hoppensteadt Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome Blood 100 13 2002 4343 4437
46. S. Coccheri, G. Biagi, G. Legnani, B. Bianchini, and F. Grauso Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man Eur. J. Clin. Pharmacol. 35 1998 151 156
47. M. Pihusch, P. Lohse, J. Bestmann, E. Hiller, R. Andreesen, and H.J. Kolb Impact of thrombophilic gene mutations and graft versus host disease on thromboembolic complications following allogeneic hematopoetic stem cell transplantation Transplantation 78 6 2004 911 918